Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2412 - Cervical cancer screening in France: recent change in behaviors


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Cancer Prevention;  Cervical Cancer


Thibault de La Motte Rouge


Annals of Oncology (2017) 28 (suppl_5): v502-v506. 10.1093/annonc/mdx383


T. de La Motte Rouge1, J. Viguier2, J. Morere3, L. Brignoli-Guibaudet4, J. Blay5, C. Lhomel6, F. Eisinger7

Author affiliations

  • 1 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2 Medical Oncology, CHRU Bretonneau, 37044 - Tours/FR
  • 3 Medical Oncology, Hopital Paul Brousse, 94804 - Villejuif/FR
  • 4 Statistics, Kantarhealth, Paris/FR
  • 5 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 6 Medical, Roche - France, 9265000 - Boulogne-Billancourt/FR
  • 7 Aix Marseille Univ, Inserm, Sesstim, Institute Paoli Calmettes, 1300674 - Marseille/FR


Abstract 2412


Cervical cancer (CC) is the fourth most common cancer in women in France. Human papillomavirus vaccination and screening are complementary secondary prevention measures against CC. Screening by conventional Pap smear is recommended every three years for women aged 25-65y.


The EDIFICE nationwide observational surveys assess population attitudes to cancer screening in general. Representative samples of the French population aged 50-75 years are interviewed by phone using the quota method. Although the French CC screening program covers all women aged 26-65y, the present analysis pertains to a subpopulation aged 50-65y (N = 356 in 2014 and N = 460 in 2016). Interviewees, with no personal history of cancer, were asked if they had ever had a smear test during a gynecological exam. The date of the last test was noted. Data analysis focused on age group, socioprofessional categories (SPC) and social vulnerability (defined by the EPICE score).


In 2016, 94% of interviewees reported at least one lifetime smear test vs. 99% in 2014 (P


Between 2014 and 2016, participation in CC screening decreased and compliance rates stagnated. Compliance with screening recommendations was negatively affected by the following: unemployment, low SPC or classification among vulnerable populations. Additional analysis will further investigate these findings, which highlight the need for generalized population-based screening programs and targeted actions for non-participants, as advocated earlier this year by the French National Cancer Institute (INCa).

Clinical trial identification

Legal entity responsible for the study

Kantar Health




T. de la Motte Rouge: Consultancy work AstraZeneca, Roche, MSD, Eisai, Sanofi Travel Grants/meeting support Roche, Novartis, Pfizer. Corporate-sponsored research Novartis. J-F. Morere, J-Y. Blay, F. Eisinger: Honorarium fees from Roche Edifice surveys were funded by Roche S.A. C. Lhomel: Employee of Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.